We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 31, 2022

Validation of Diagnostic Tests Based on BC-116 and BC-106 Urine Peptide Biomarkers for Bladder Cancer

British Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Cancer
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients
Br. J. Cancer 2022 Oct 03;[EPub Ahead of Print], L Mengual, M Frantzi, M Mokou, M Ingelmo-Torres, M Vlaming, AS Merseburger, MC Roesch, Z Culig, A Alcaraz, A Vlahou, H Mischak, AG Van der Heijden

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading